The Healing Touch Pharmaceuticals

Inonza 1mg refers to the medication Inotuzumab ozogamicin, which is a targeted therapy used primarily in the treatment of certain types of acute lymphoblastic leukemia (ALL), particularly in patients who have relapsed or are refractory (not responding to treatment) to previous therapies. Inotuzumab ozogamicin is a monoclonal antibody conjugated with a chemotherapy drug. The monoclonal antibody targets a protein called CD22, which is present on the surface of B-cell leukemia cells. The chemotherapy drug is delivered directly to the leukemia cells through the antibody, allowing for more precise treatment with reduced impact on healthy cells. It is typically administered by injection or infusion, under the supervision of a healthcare professional, because it can have serious side effects, including liver toxicity, infections, and hematologic issues such as low blood counts.